Achilles Therapeutics plc - ADR (ACHL)
NASDAQ (CM) 
Summary
ACHL Chart
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024.
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Achilles Therapeutics plc - ADR (ACHL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Achilles Therapeutics plc - ADR ever had a stock split?
Achilles Therapeutics plc - ADR Profile
| Biotechnology Industry | Healthcare Sector | Dr. Iraj Ali Ph.D. CEO | NASDAQ (CM) Exchange | US00449L1026 ISIN |
| United Kingdom Country | 204 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Achilles Therapeutics plc is a renowned biopharmaceutical entity dedicated to the innovation of precise T cell therapies aimed at the combat against solid tumors. With a pioneering approach that identifies mutations arising early in cancer development, Achilles Therapeutics has established itself as a leader in the field. Originally known as Achilles TX Limited, the company underwent a rebranding to Achilles Therapeutics Plc in February 2021, marking a significant milestone in its evolution. Founded in the year 2016, Achilles Therapeutics maintains its headquarters in London, the United Kingdom, testament to its commitment to advancing cancer treatment on a global scale.
Products and Services
- PELEUS
An advanced proprietary AI-powered bioinformatics platform developed by Achilles Therapeutics. PELEUS is designed to identify clonal neoantigens within a patient, revolutionizing the approach to personalized cancer therapy. This tool harnesses the power of artificial intelligence to uncover unique mutations, enabling the creation of highly targeted treatment plans for individuals battling cancer.
- CHIRON
CHIRON represents a cutting-edge product candidate from Achilles Therapeutics, currently undergoing Phase I/IIa clinical trials. This revolutionary therapy is being explored for its potential to treat advanced non-small cell lung cancer, offering hope to patients seeking alternatives in their fight against this challenging disease. Through meticulous research and clinical testing, CHIRON aims to demonstrate efficacy and safety, marking a significant breakthrough in cancer treatment.
- THETIS
Another promising product candidate from Achilles Therapeutics is THETIS, which is also in Phase I/IIa clinical trials. Specifically targeting metastatic or recurrent melanoma, THETIS embodies the company's dedication to combating the most aggressive and resistant forms of cancer. By focusing on such a critical area of need, Achilles Therapeutics is at the forefront of developing innovative treatments that could significantly impact patients' lives.
Contact Information
